Locally instilled tumor necrosis factor α antisense oligonucleotide contributes to inhibition of TH2-driven pulmonary fibrosis via induced CD4+CD25+Foxp3+ regulatory T cells

Journal of Gene Medicine

Volumn 15, Issue 11-12, 2013, Pages 441-452

  Luo, Yi ^a   Wang, Min ^a   Pang, Zhonghua ^a   Jiang, Fengtao ^a   Chen, Jiangning ^a   Zhang, Junfeng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Anti TNF therapeutics; Antisense oligonucleotide; Pulmonary fibrosis; Regulatory T cells; TH2 biased responses

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BLEOMYCIN; ISIS 25302; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; MOUSE; MOUSE MODEL; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TH2 CELL; THYMUS; WESTERN BLOTTING;

ANTI-TNF-Α THERAPEUTICS; ANTISENSE OLIGONUCLEOTIDE; PULMONARY FIBROSIS; REGULATORY T CELLS; TH2-BIASED RESPONSES;

4-1BB LIGAND; ACTINS; ANIMALS; ANTIGENS, CD4; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG; MICE; OLIGONUCLEOTIDES, ANTISENSE; PULMONARY FIBROSIS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84891102808     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2750     Document Type: Article

References (38)

1. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
2. Thannickal VJ, Toews GB, White ES, et al. Mechanisms of pulmonary fibrosis. Annu Rev Med 2004; 55: 395-417.
3. Wynn TA. Fibrotic disease and the TH1/TH2 paradigm. Nat Rev Immunol 2004; 4: 583-594.
4. Zhang Y, Lee TC, Guillemin B, et al. Enhanced IL-1 beta and tumour necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol 1993; 150: 4188-4196.
5. Piguet PF, Collart MA, Grau GE, et al. Tumour necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med 1989; 170: 655-663.
6. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumour necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995; 96: 250-9.
7. Piguet PF, Ribaux C, Karpuz V, et al. Expression and localization of tumour necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143: 651-655.
8. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-518.
9. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumour necrosis factor-alpha inhibition. Chest 2002; 122: 1093-1096.
10. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
11. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
12. Thavarajah K, Wu P, Rhew EJ, et al. Pulmonary complications of tumour necrosis factor-targeted therapy. Respir Med 2009; 103: 661-669.
13. Piguet PF, Collart MA, Grau GE, et al. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990; 344: 245-247.
14. Ortiz LA, Lasky J, Hamilton RF Jr, et al. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 721-743.
15. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumour necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162: 755-758.
16. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125-140.
17. Li X, Zhuang J, Rayford H, et al. Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA. Curr Pharm Des 2007; 13: 1257-1268.
18. Hagiwara S, Iwasaka H, Matsumoto S, et al. Antisense oligonucleotide inhibition of heat shock protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats. Respir Res 2007; 8: 37-47.
19. Zeng M, Liao B, Zhu C, et al. Aerosolized STAT1 antisense oligodeoxynucleotides decrease the concentrations of inflammatory mediators in bronchoalveolar lavage fluid in bleomycin-induced rat pulmonary fibrosis. Cell Mol Immunol 2008; 5: 219-224.
20. Guimond A, Viau E, Aubé P, et al. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 2008; 21: 845-54.
21. Zuo L, Huang Z, Dong L, et al. Targeting delivery of anti-TNF-α oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010; 59: 470-479.
22. Luo Y, Pang Z, Zhu Q, et al. Locally instilled tumour necrosis factor-α antisense oligonucleotide inhibits allergic inflammation via the induction of Tregs. J Gene Med 2012; 14: 374-383.
23. Sempowski GD, Beckmann MP, Derdak S, et al. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994; 152: 3606-3614.
24. Doucet C, Brouty-Boyé D, Pottin-Clémenceau C, et al. Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma. J Clin Invest 1998; 101: 2129-2139.
25. Reiman RM, Thompson RW, Feng CG, et al. Interleukin-5 (IL-5) augments the progression of liver fibrosis by regulating IL-13 activity. Infect Immun 2006; 74: 1471-1479.
26. Wynn TA, Cheever AW, Jankovic D, et al. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376: 594-596.
27. Hesse M, Cheever AW, Jankovic D, et al. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 2000; 157: 945-955.
28. Venuprasad K, Kong YC, Farrar MA. Control of Th2-mediated inflammation by regulatory T cells. Am J Pathol 2010; 177: 525-531.
29. + regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1121-1130.
30. Boveda-Ruiz D, D'Alessandro-Gabazza CN, Toda M, et al. Differential role of regulatory T cells in early and late stages of pulmonary fibrosis. Immunobiology 2013; 218: 245-254.
31. + T cell levels in NOD mice. Proc Natl Acad Sci U S A 2002; 99: 12, 287-12, 292.
32. + T cells that inhibit protective immunity in murine histoplasmosis. J Immunol 2008; 180: 1088-1097.
33. Beier KC, Kallinich T, Hamelmann E. Master switches of T-cell activation and differentiation. Eur Respir J 2007; 29: 804-12.
34. + regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol 2003; 226: 20-29.
35. + T cells. J Leukoc Biol 2004; 75: 785-791.
36. + regulatory T cells. J Immunol 2004; 173: 2428-2434.
37. Seo SK, Park HY, Choi JH, et al. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol 2003; 171: 576-583.
38. + T cells that inhibit protective immunity in murine histoplasmosis. J Immunol 2008; 180: 1088-1097.